{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:03:51Z","timestamp":1789621431858,"version":"build-2803163510"},"reference-count":45,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Benign prostatic hyperplasia (BPH) commonly presents with lower urinary tract symptoms (LUTS), which can significantly impair quality of life in aging men. Tamsulosin, a selective alpha-1 blocker, is widely used for symptom relief. Tadalafil, a phosphodiesterase-5 inhibitor, offers dual benefit for LUTS and erectile dysfunction (ED). However, limited comparative data exist from African populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of tadalafil and tamsulosin monotherapy in the management of LUTS due to BPH in men attending a tertiary hospital in Ghana.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective, randomized, open-label study was conducted over 12\u2009weeks at the Korle-Bu Teaching Hospital. Eighty-two men aged\u2009\u2a7e40\u2009years with moderate to severe LUTS due to BPH were randomized to receive either tadalafil 5\u2009mg or tamsulosin 0.4\u2009mg daily. Baseline, 4-week, and 12-week evaluations included International Prostate Symptom Score (IPSS), quality of life (QoL), peak urinary flow rate (Qmax), post-void residual urine (PVR), and International Index of Erectile Function (IIEF-5). Statistical analyses included t-tests and linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Both groups showed significant improvement in IPSS, QoL, Qmax, and PVR over time. At 12\u2009weeks, Qmax was significantly higher in the tadalafil group compared to tamsulosin (18.7\u2009\u00b1\u20094.5 vs 16.9\u2009\u00b1\u20092.6\u2009mL\/s,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.045). IPSS improvement was similar across both arms (Tadalafil: \u22129.3; Tamsulosin: \u22127.8). Tadalafil significantly improved IIEF-5 scores from 14.0 to 21.0 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas tamsulosin showed minimal change. Subgroup analysis showed tadalafil\u2019s erectile function benefit was consistent across demographic and clinical subgroups except in diabetics. Side effects were mild (5.1%) and equally distributed between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Tadalafil and tamsulosin are both effective in alleviating LUTS due to BPH. Tadalafil provides additional benefits in erectile function and superior improvement in urinary flow, making it a suitable first-line option, especially for patients with coexisting ED. These findings support individualized treatment decisions based on patient profile and symptom burden in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261421800","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:49:51Z","timestamp":1771210191000},"page":"409-420","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tadalafil and tamsulosin in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: A prospective, randomized, open-label, comparative study"],"prefix":"10.1177","volume":"93","author":[{"given":"Enoch","family":"Tackie","sequence":"first","affiliation":[{"name":"Department of Surgery, Korle-Bu Teaching Hospital, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew Yamoah","family":"Kyei","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Ghana Medical School, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4133-1722","authenticated-orcid":false,"given":"James Edward","family":"Mensah","sequence":"additional","affiliation":[{"name":"Department of Surgery, Korle-Bu Teaching Hospital and University of Ghana Medical School, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"289","volume-title":"The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates","author":"Egan KB.","year":"2016","unstructured":"Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America. W.B. Saunders, 2016. Vol. 43, pp.289\u2013297."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2011.43"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2006.08.008"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12745"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.037"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287213488236"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00127-7"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.06.004"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20999"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287214531639"},{"issue":"2","key":"e_1_3_3_12_2","first-page":"207","article-title":"EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS)","volume":"84","author":"Cornu J","year":"2023","unstructured":"Cornu J, Gacci M, Hashim H, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS). Eur Assoc Urol 2023; 84(2): 207\u2013222.","journal-title":"Eur Assoc Urol"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002231"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2024.13098"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/03915603241258697"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/and.13125"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01091-8"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.600"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13530"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12357"},{"issue":"2","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2012.05.012","article-title":"Re: Matthias Oelke, Fran\u00e7ois Giuliano, Vincenzo Mirone, Lei Xu, David Cox, Lars Viktrup. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Goyal NK","year":"2012","unstructured":"Goyal NK, Goel A, Yadav R. Re: Matthias Oelke, Fran\u00e7ois Giuliano, Vincenzo Mirone, Lei Xu, David Cox, Lars Viktrup. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61:917-25. Eur Urol 2012; 62(2): e39.","journal-title":"Eur Urol"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.923179"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.23027"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.10.01"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.01.013"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-063014-123902"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219020-00004"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000351405"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.09.057"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09687.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.01.013"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12039"},{"issue":"1","key":"e_1_3_3_33_2","first-page":"44","article-title":"Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized","volume":"72","author":"Pogula VR","year":"2019","unstructured":"Pogula VR, Kadiyala LS, Gouru VR, et al. Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized. Cent Eur J Urol 2019; 72(1): 44\u201350.","journal-title":"Cent Eur J Urol"},{"issue":"7","key":"e_1_3_3_34_2","first-page":"333","article-title":"Assessment of lower urinary tract symptoms","volume":"34","author":"Khan SJ","year":"2016","unstructured":"Khan SJ, Khastgir J. Assessment of lower urinary tract symptoms. Surg 2016; 34(7): 333\u2013341.","journal-title":"Surg"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12144"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02821.x"},{"issue":"1","key":"e_1_3_3_37_2","article-title":"Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial","volume":"189","author":"Dmochowski R","year":"2013","unstructured":"Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2013; 189(1): S135\u2013S140.","journal-title":"J Urol"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-024-01199-4"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12733"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15060726"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245788"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.4103\/JAPTR.JAPTR_87_24"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7906"},{"issue":"4","key":"e_1_3_3_44_2","first-page":"639","article-title":"Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"69","author":"Zabkowski T","year":"2018","unstructured":"Zabkowski T, Saracyn M. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol 2018; 69(4): 639.","journal-title":"J Physiol Pharmacol"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/15579883231155096"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.744012"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261421800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261421800","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261421800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:32:30Z","timestamp":1789619550000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261421800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/03915603261421800"],"URL":"https:\/\/doi.org\/10.1177\/03915603261421800","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}